MabPlex International Ltd. Secures $59.1 Million Series A Financing Round

Share Article

MabPlex International Ltd, a leading, global Contract Development and Manufacturing Organization (CDMO ), has closed its series A funding of $59.1 million. This financing, backed by multiple global investors lead by China's State Development & Investment Corporation (SDIC) and Shenzhen Venture capital, will support the upgrades to MabPlex’s technology platform as well as Phase III and commercial production expansion. Funding will also support the company’s international strategy.

MabPlex International Ltd - Logo

This series A financing round will support upgrades to MabPlex’s technology platform, Phase III and commercial production expansion, as well as the company’s international strategy and greatly enhance the company's capabilities to continue to provide high quality services to it's customers.

MabPlex International Ltd, a leading and fully integrated Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and the United States, has closed its series A funding of $59.1 million backed by multiple global investors lead by China's State Development & Investment Corporation (SDIC) and Shenzhen Venture capital. 

This financing round will support upgrades to MabPlex’s technology platform, Phase III and commercial production expansion, as well as the company’s international strategy.

"With our professional services and international standards, R&D companies can not only shorten product development time, but more importantly, they can use limited funds for new drug projects themselves, reduce R&D risks and increase corporate value," said Jianmin Fang, Ph.D, Chairman and Chief Executive Officer of MabPlex International, Ltd.

"This financing will greatly enhance our service capabilities, we will continue to provide high quality services to our customers," Fang added.

About MabPlex
MabPlex International Ltd, a leading and fully integrated Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global biopharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing. With our state-of-the-art facilities and exemplary biologics development and manufacturing experience, MabPlex commits to being a valuable partner for our clients around the globe.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bethanne Deuel, MBA
Visit website